Halt Aging in Survivors of Blood Cancers: the HALTAging-1 Study (NCT07292272) | Clinical Trial Compass
Not Yet RecruitingPhase 2
Halt Aging in Survivors of Blood Cancers: the HALTAging-1 Study
United States180 participantsStarted 2026-03-01
Plain-language summary
Older survivors of blood cancer are at a high risk of accelerated biological aging, which increases their risk of developing multiple aging-related conditions. Whereas physical exercise can improve overall health, older cancer survivors do not meet the recommended physical activity, highlighting the need to develop behavioral interventions to increase adherence. Several other knowledge gaps exist to implement exercise interventions in older survivors of blood cancer; the dose and duration of exercise necessary to slow biological aging in older blood cancer survivors remain unknown. To bridge these gaps in knowledge, we have designed a Phase 2 randomized control trial to test the effects of behavioral and exercise interventions on various outcomes.
Who can participate
Age range50 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Age ≥50 years
✓. A history of hematological malignancy
✓. Participants must be able to and willingly give informed consent
Exclusion criteria
✕. Patients receiving intensive induction or consolidation chemotherapy. Maintenance chemotherapy, or lower-intensity chemotherapy for an indolent hematological malignancy is allowed.
✕. Neurodegenerative disease (e.g. Alzheimer's dementia), stroke, or uncontrolled psychotic disorders (e.g. schizophrenia or bipolar disorder) in the past 3 months if those disorders are considered significant enough to impair participation in the study.
✕. Illnesses such as clinical evidence of decompensated heart failure, unstable angina, or orthopedic or neuromuscular disorders that could limit safe participation in aerobic exercise.
✕. Cardiopulmonary exercise test results that preclude safe exercise (e.g., life-threatening arrhythmia, balance difficulties, peak VO2 \<10 ml/kg/min).
✕. Estimated life expectancy of less than 6 months (that precludes assessment of study primary endpoint).
What they're measuring
1
Percentage of participants who adhered to the exercise regimen at 6-months post enrollment.
Timeframe: 6 Months from start of program
2
Percentage of participants who adhered to the exercise regimen at 12-months post enrollment.